The partnership between Radiometer and Perimed will give Radiometer the ability to sell Perimed’s unique wound care system and give Perimed the ability to expand the reach of their product through Radiometer’s strong distribution network.
Brønshøj, January 8, 2019. 10.00 CET
Radiometer Medical ApS (Radiometer) partners with Perimed AB (Perimed) to accelerate and expand the distribution of the Perimed PeriFlux 6000 tcpO2 standalone system. The partnership will combine Radiometer’s strong, direct and established commercial network with Perimed’s state-of-the-art system, thus allowing a wider range of customers and patients to benefit from the capabilities of the product.
“At Radiometer, our vision is to improve global healthcare with reliable, fast and easy diagnoses,” says Henrik Schimmell, President and CEO of Radiometer. “We strive hard to meet the needs and even surpass the expectations of our customers. The PeriFlux 6000 tcpO2 standalone system is the latest generation of transcutaneous monitoring and we’re excited to obtain the distribution rights of the device and further expand its position in the market.”
The Periflux 6000 tcpO2 standalone system will be an addition to Radiometer’s existing portfolio of transcutaneous monitoring systems, designed to provide non-invasive measurements of oxygenation status. The PeriFlux 6000 tcpO2 standalone system provides health care professionals with a reliable and easy tool to support wound healing predictions and will replace Radiometer’s TCM400.
“Perimed’s mission is to improve the quality of life for people suffering from vascular diseases, by supplying diagnostic instruments in the field of microcirculation and peripheral macro circulation,” says Björn Bakken, President of Perimed. “We have good products, but our sales capacity is limited. Radiometer’s sales capability and knowledge in tcpO2 is undisputed and we’re excited to have entered into this partnership. We hope this cooperation will lead to improved diagnostic capability in the wound care and hyperbaric sector.”
The PeriFlux 6000 tcpO2 standalone system will initially be launched in the US with other markets to follow. As part of the launch in the US, Radiometer will take over the support of Perimed’s existing and future users of the PeriFlux 6000 tcpO2 standalone.
Perimed will continue to sell and support all PeriFlux 6000 cart based systems that contains a PC, and measures toe-pressure, SPP, or tcpO2 in combination with Toe-pressure or SPP. Perimed will also continue to support the older PeriFlux 5000 Systems and the Perimed Imager range of instruments.
Radiometer is a leading provider of technologically advanced acute care solutions that simplify and automate all phases of acute care testing.
Radiometer develops, manufactures and markets solutions for blood sampling, blood gas analysis, transcutaneous monitoring, immunoassay testing and the related IT management systems.
Perimed is a world leader in developing, manufacturing and marketing state-of-the-art equipment for microvascular diagnosis.
Perimed provides instruments, software and expertise to enable assessment of the microcirculation. Through utilization of laser Doppler, laser speckle (LASCA) and transcutaneous oxygen (tcpO2 or TCOM), Perimed accurately monitor and quantify blood perfusion and tissue oxygenation in real-time.
Senior Manager, Communications & CSR, Radiometer ApS
+45 3029 3331
President, Perimed AB
+46 739 82 41 36